$901 Million is the total value of Boxer Capital, LLC's 24 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 30.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SLDB | Buy | SOLID BIOSCIENCES INC | $135,954,000 | +37.3% | 2,881,600 | +3.7% | 15.09% | +34.5% |
| BGNE | BEIGENE LTDsponsored adr | $108,499,000 | +12.0% | 630,000 | 0.0% | 12.04% | +9.8% | |
| PTCT | Buy | PTC THERAPEUTICS INC | $101,285,000 | +58.0% | 2,155,000 | +13.4% | 11.24% | +54.9% |
| WVE | WAVE LIFE SCIENCES LTD | $79,530,000 | +30.7% | 1,590,600 | 0.0% | 8.82% | +28.1% | |
| MRTX | MIRATI THERAPEUTICS INC | $73,738,000 | -4.5% | 1,565,560 | 0.0% | 8.18% | -6.4% | |
| ESPR | ESPERION THERAPEUTICS INC NE | $61,009,000 | +13.2% | 1,375,000 | 0.0% | 6.77% | +10.9% | |
| ODT | ODONATE THERAPEUTICS INC | $54,871,000 | -12.1% | 2,826,938 | 0.0% | 6.09% | -13.9% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $48,404,000 | +25.4% | 1,966,051 | 0.0% | 5.37% | +22.9% | |
| MDCO | Buy | MEDICINES CO | $41,874,000 | -8.7% | 1,400,000 | +12.0% | 4.65% | -10.5% |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $33,690,000 | +64.0% | 1,500,000 | +40.8% | 3.74% | +60.7% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $32,704,000 | +187.8% | 400,000 | +23.1% | 3.63% | +182.0% |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $29,904,000 | +47.0% | 1,172,700 | 0.0% | 3.32% | +44.0% | |
| CBAY | CYMABAY THERAPEUTICS INC | $23,202,000 | -17.4% | 2,094,000 | 0.0% | 2.58% | -19.1% | |
| AMRN | New | AMARIN CORP PLCspons adr new | $21,151,000 | – | 1,300,000 | +100.0% | 2.35% | – |
| KURA | KURA ONCOLOGY INC | $14,784,000 | -3.8% | 844,789 | 0.0% | 1.64% | -5.8% | |
| MEIP | MEI PHARMA INC | $12,555,000 | +9.4% | 2,913,091 | 0.0% | 1.39% | +7.2% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $7,453,000 | +13.4% | 2,321,900 | 0.0% | 0.83% | +11.2% | |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $4,422,000 | – | 200,000 | +100.0% | 0.49% | – |
| SNSS | SUNESIS PHARMACEUTICALS INC | $4,250,000 | -5.7% | 2,125,000 | 0.0% | 0.47% | -7.5% | |
| RGLS | REGULUS THERAPEUTICS INC | $4,026,000 | +259.1% | 1,697,802 | 0.0% | 0.45% | +252.0% | |
| XENE | New | XENON PHARMACEUTICALS INC | $3,960,000 | – | 300,000 | +100.0% | 0.44% | – |
| BLPH | Sell | BELLEROPHON THERAPEUTICS INC | $1,601,000 | -64.4% | 1,482,143 | -20.2% | 0.18% | -65.0% |
| NVUS | NOVUS THERAPEUTICS INC | $1,515,000 | -33.3% | 324,383 | 0.0% | 0.17% | -34.6% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $808,000 | +15.1% | 100,000 | 0.0% | 0.09% | +13.9% | |
| GTXI | Exit | GTX INC DEL | $0 | – | -1,310,000 | -100.0% | -2.27% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -1,245,000 | -100.0% | -2.91% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -95,000 | -100.0% | -3.01% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -3,750,000 | -100.0% | -4.03% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -375,000 | -100.0% | -5.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.